Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update.

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver Cancer Pub Date : 2024-09-03 eCollection Date: 2025-04-01 DOI:10.1159/000541249

Xinyu Bi, Haitao Zhao, Hong Zhao, Guangming Li, Xiaodong Wang, Bo Chen, Wen Zhang, Xu Che, Zhen Huang, Yue Han, Liming Jiang, Yongkun Sun, Zhengqiang Yang, Jianguo Zhou, Yefan Zhang, Zhenyu Zhu, Minshan Chen, Shuqun Cheng, Jianqiang Cai

{"title":"Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update.","authors":"Xinyu Bi, Haitao Zhao, Hong Zhao, Guangming Li, Xiaodong Wang, Bo Chen, Wen Zhang, Xu Che, Zhen Huang, Yue Han, Liming Jiang, Yongkun Sun, Zhengqiang Yang, Jianguo Zhou, Yefan Zhang, Zhenyu Zhu, Minshan Chen, Shuqun Cheng, Jianqiang Cai","doi":"10.1159/000541249","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is a common malignancy in China, with high recurrence rate and low resection rate among patients first diagnosed. Preoperative treatments including neoadjuvant and conversion therapy have the potential to overcome these challenges. In December 2021, Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma was published. With the emersion of new evidence regarding the neoadjuvant and conversion therapies for HCC, the cooperative group brought together multidisciplinary researchers and scholars with experience in related fields to update the new edition (2023 Edition) for reference in China, including principle of the treatment strategies, the potential populations selection, treatment methods, multidisciplinary team, and future research for preoperative treatments. The new consensus aims to provide guidance for clinical application. Through the use of neoadjuvant therapy and conversion therapy, we can enhance the resection rate and reduce the recurrence of intermediate-to-advanced HCC patients, thereby improving survival outcomes.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"223-238"},"PeriodicalIF":11.6000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005702/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541249","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy in China, with high recurrence rate and low resection rate among patients first diagnosed. Preoperative treatments including neoadjuvant and conversion therapy have the potential to overcome these challenges. In December 2021, Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma was published. With the emersion of new evidence regarding the neoadjuvant and conversion therapies for HCC, the cooperative group brought together multidisciplinary researchers and scholars with experience in related fields to update the new edition (2023 Edition) for reference in China, including principle of the treatment strategies, the potential populations selection, treatment methods, multidisciplinary team, and future research for preoperative treatments. The new consensus aims to provide guidance for clinical application. Through the use of neoadjuvant therapy and conversion therapy, we can enhance the resection rate and reduce the recurrence of intermediate-to-advanced HCC patients, thereby improving survival outcomes.

查看原文本刊更多论文

中国专家关于肝细胞癌新辅助治疗和转化治疗的共识：2023年更新。

肝细胞癌（HCC）在中国是一种常见的恶性肿瘤，首次诊断的患者复发率高，切除率低。术前治疗包括新辅助治疗和转换治疗有可能克服这些挑战。2021年12月，发表了中国肝癌新辅助治疗和转化治疗专家共识。随着肝癌新辅助治疗和转化治疗的新证据的出现，合作小组汇集了多学科研究人员和相关领域有经验的学者，更新了新版（2023版），供国内参考，包括治疗策略原则、潜在人群选择、治疗方法、多学科团队以及术前治疗的未来研究。新的共识旨在为临床应用提供指导。通过新辅助治疗和转化治疗，可以提高中晚期HCC患者的切除率，减少复发，从而改善生存结局。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Liver Cancer Medicine-Oncology

CiteScore

20.80

自引率

7.20%

发文量

审稿时长

16 weeks

期刊介绍： Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.